Johnson & Johnson Maintains Strong Growth Prospects According to Goldman Sachs
Goldman Sachs has added Johnson & Johnson (JNJ) to its U.S. May Directors’ Cut Conviction List, citing strong investment potential based on the company's recent performance and outlook. J&J reported Q1 sales of $24.1 billion with a year-over-year increase of 9.9%.
Topics: defensive growth strategy earnings report Goldman Sachs Conviction List Johnson & Johnson